Invention Grant
US08394385B2 Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
有权
优化的早期启动子结合反复接种有利于MVA疫苗中针对重组抗原的细胞毒性T细胞应答
- Patent Title: Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
- Patent Title (中): 优化的早期启动子结合反复接种有利于MVA疫苗中针对重组抗原的细胞毒性T细胞应答
-
Application No.: US12719987Application Date: 2010-03-09
-
Publication No.: US08394385B2Publication Date: 2013-03-12
- Inventor: Jürgen Hausmann , Karen Baur , Kay Brinkmann
- Applicant: Jürgen Hausmann , Karen Baur , Kay Brinkmann
- Applicant Address: DK Kvistgaard
- Assignee: Bavarian Nordic A/S
- Current Assignee: Bavarian Nordic A/S
- Current Assignee Address: DK Kvistgaard
- Agency: Law Office of Salvatore Arrigo and Scott Lee, LLP
- Priority: EP09009759 20090728
- Main IPC: A61K39/275
- IPC: A61K39/275 ; A61K39/285 ; A61K39/12 ; A61K48/00 ; A01N63/00 ; A01N65/00 ; C12Q1/70 ; C12N15/00
Abstract:
The invention is drawn to compositions and methods for the induction of a strong CD8 T cell response to a specific antigen(s). The combination of an early/late hybrid promoter directing strongly enhanced early expression of a neoantigen with at least three immunization rounds resulted in a highly efficient neoantigen-specific CD8 T cell response. This combination reversed the immunodominance hierarchy and converted a moderately immunogenic and subdominant CD8 T cell epitope into the immunodominant epitope.
Public/Granted literature
Information query
